Q-omics provides the consensus-scored HS6ST2 profile across patient tissues and cancer cell-line models. HS6ST2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HS6ST2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, HS6ST2 RNA expression shows 18,003 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where HS6ST2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HS6ST2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HS6ST2 survival associations across molecular data types. HS6ST2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HS6ST2 RNA expression–survival associations across cancer types. High HS6ST2 expression shows unfavorable associations in KIRC, UVM, LIHC, ACC and STAD, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HS6ST2 RNA expression.
This table summarizes HS6ST2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HS6ST2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HS6ST2 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in COAD, BLCA and LUAD. The KIRC box plot shows higher HS6ST2 RNA expression in normal versus tumor tissue (log2 FC = −4.332, t-test p < 0.001).
This table shows molecular features associated with HS6ST2 in patient tissues and cancer cell lines. In patient samples, HS6ST2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HS6ST2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
